The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
Alport syndrome, from childhood to adulthood including transition
Video resources
*The specific content of these links is part of this specific e-seminar, therefore ERA has no responsibility